Monitoring autophagic flux on high throughput platforms shouldn't be limited by prior transfection, buffer changes or the frustrations of photobleaching.

New Autophagic Flux & Apoptosis Reagents available for FREE Evaluation.

PLUG & PLAY. NO TRANSFECTION. NO WASH.

Apop Biosciences Pty Ltd (Apop) has entered into a worldwide out-license agreement with a U.S.-based company for Apop’s monoclonal antibody technology. Through this agreement, Apop will grant non-exclusive global rights to the licensee to develop, manufacture, and commercialize products that will incorporate Apop’s patented technology.

Apop Bioscience CEO, Elpis Barons with be in the San Diego, USA in the first week of June to attend Bio International, and keen to meet with investors, biotech, biopharma, distributors, CROs, scientists. Either reach out to Elpis via the contact form, or if you have joined bio-partnering, reach out so we can schedule a meeting.

Australasian Cytometry Society Conference - 27-30 August 2023, Queenstown, New Zealand | Our CSO, A/Prof. Peter Wookey, is presenting the further advances in Apop’s imaging tools for the detection of apoptosis.

Join us at the 2023 ASI Advanced Immunology School Conference in Adelaide 14-16 August 2023, for the latest advances in Apop’s imaging tools for apoptosis and autophagy.

CSO Peter Wookey is presenting at JAM, the 3rd Japan & Australia Meeting on Cell Death from 16 to 18 Aug at WEHI

Apop Biosciences’ CalRexin™:568 research reagent is independently validated for FACS by Crux Biolabs